Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) Invested Capital: 2016-2025

Historic Invested Capital for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to $192.3 million.

  • Summit Therapeutics' Invested Capital fell 56.10% to $192.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.3 million, marking a year-over-year decrease of 56.10%. This contributed to the annual value of $388.7 million for FY2024, which is 400.37% up from last year.
  • Per Summit Therapeutics' latest filing, its Invested Capital stood at $192.3 million for Q3 2025, which was down 25.89% from $259.4 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Invested Capital high stood at $437.9 million for Q3 2024, and its period low was $44.2 million during Q1 2024.
  • Moreover, its 3-year median value for Invested Capital was $192.3 million (2025), whereas its average is $208.4 million.
  • Per our database at Business Quant, Summit Therapeutics' Invested Capital slumped by 66.88% in 2024 and then soared by 678.85% in 2025.
  • Over the past 5 years, Summit Therapeutics' Invested Capital (Quarterly) stood at $83.3 million in 2021, then skyrocketed by 52.07% to $126.7 million in 2022, then crashed by 38.66% to $77.7 million in 2023, then skyrocketed by 400.37% to $388.7 million in 2024, then tumbled by 56.10% to $192.3 million in 2025.
  • Its Invested Capital was $192.3 million in Q3 2025, compared to $259.4 million in Q2 2025 and $344.3 million in Q1 2025.